Aurinia Pharmaceuticals loss under IFRS for 6 months of 2020 was $46.06 million, an increase of 62.6% compared to $28.329 million in the previous year. Revenues remained at the level of the previous year, amounting to $59 thousand.
Aurinia Pharmaceuticals loss under IFRS for 6 months of 2020 was $46.06 million, an increase of 62.6% compared to $28.329 million in the previous year. Revenues remained at the level of the previous year, amounting to $59 thousand. 
ir.auriniapharma.com
English (US) 